Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

S*BIO Lands Another $20 Million from Onyx

publication date: May 5, 2010
View a Printer Friendly version of this page, allowing you to print the page.
S*BIO Pte Ltd., a clinical stage Singapore biotech, has signed a new $20 million deal with Onyx Pharmaceuticals to expand the development of S*BIO's novel JAK2 inhibitors, SB1518 and SB1578. S*BIO will use the money to explore new indications for hematologic malignancies and myeloproliferative disorders. The two companies signed their original $25 million agreement in January 2009. More details...

Stock Symbol: (NSDQ: ONXX)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China